By DEENA BEASLEY Researchers at the University of Pennsylvania engineered patients’ own pathogen-fighting T-cells to target a molecule found on the surface of leukemia cells. The altered T-cells were grown outside of the body and infused back into patients suffering from late-stage chronic lymphocytic leukemia (CLL), which affects the blood and bone marrow and is…
By TIA GHOSE The debt ceiling proposal that passed the House of Representatives on Monday (August 1) will likely cause deep spending cuts for government scientific research if the Senate passes the bill this afternoon. Though the details won’t be ironed out until at least November, the proposed bill will raise the debt ceiling and mandate at…
By TIA GHOSE The debt ceiling proposal that passed the House of Representatives on Monday (August 1) will likely cause deep spending cuts for government scientific research if the Senate passes the bill this afternoon. Though the details won’t be ironed out until at least November, the proposed bill will raise the debt ceiling and mandate at…
By MARGARET HAMBURG There are encouraging signs that the pharmaceutical industry’s pipeline of new products is not as stalled as some say. Already in 2011, the Food and Drug Administration (FDA) has approved 21 new, groundbreaking medicines—the same number as in all of 2010—including treatments for Hepatitis C, late-stage prostate cancer and lupus. We hope…
By MARGARET HAMBURG There are encouraging signs that the pharmaceutical industry’s pipeline of new products is not as stalled as some say. Already in 2011, the Food and Drug Administration (FDA) has approved 21 new, groundbreaking medicines—the same number as in all of 2010—including treatments for Hepatitis C, late-stage prostate cancer and lupus. We hope…
By JONATHAN D. ROCKOFF And RON WINSLOW The pharmaceutical industry, after years of research flops that led some to write its obituary, shows signs it is coming back to life. Credit a revamped research approach by the industry, which, after years of focusing on me-too drugs for ills that were already well treated, is pouring firepower into diseases…
By JONATHAN D. ROCKOFF And RON WINSLOW The pharmaceutical industry, after years of research flops that led some to write its obituary, shows signs it is coming back to life. Credit a revamped research approach by the industry, which, after years of focusing on me-too drugs for ills that were already well treated, is pouring firepower into diseases…
By Ellen Sigal, The Food and Drug Administration has been portrayed by many critics as slow and inefficient compared with the regulatory agencies of other countries. This criticism is of particular concern in the field of cancer, where severely ill patients have few effective treatment options. But a new study conducted by Friends of Cancer…
By Ellen Sigal, The Food and Drug Administration has been portrayed by many critics as slow and inefficient compared with the regulatory agencies of other countries. This criticism is of particular concern in the field of cancer, where severely ill patients have few effective treatment options. But a new study conducted by Friends of Cancer…
By LISA RICHWINE The findings released on Thursday counter a common belief among doctors, academics and investors that new oncology drugs often win approval in Europe first, said researchers from the nonprofit advocacy group Friends of Cancer Research. Each of the 23 cancer drugs cleared by the United States and Europe over a seven-year period…
